Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...

This segment centers on the landmark EMBARK trial, which demonstrated a significant overall survival benefit with enzalutamide plus leuprolide. Freedland discusses the clinical implications of these ...

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population. In this video, Jen-Jane Liu, MD, ...

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

"I'm very excited to bring this therapy to our patients in the Philadelphia area and to be able to offer it at MidLantic," says David Cahn, DO, MBS, FACOS. "For me and the patients, [nadofaragene ...

The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.

Dornier single-use ureteroscope and ureteral access sheath launch on US market ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...